Eli Lilly (NYSE: LLY) is the top healthcare company in the world. Investors have been paying a big premium for the business and its future growth, propelling it to all-time highs this year. Is there still room for the stock to rise even higher, or is it approaching a peak?
This past Tuesday, Eli Lilly posted its most recent quarterly results for the last three months of 2023. Revenue rose 28% to $9.4 billion from the same period last year.
Mounjaro, the company's diabetes medication, has taken over the top spot as the company's top-selling drug, unseating Trulicity. Mounjaro's sales last quarter totaled $2.2 billion (versus just $279 million a year ago), while Trulicity came in at under $1.7 billion, its sales declining by 14% year over year.
Source Fool.com